Balancing Clinical and Patient-Centered Factors in 1L EGFRm NSCLC Treatment

Patient-Centered Factors in Treatment Decision-Making

Main Discussion Topics:

• Incorporating patient goals and preferences into treatment selection
• Approaches to shared decision-making in time-limited clinical visits
• Use of risk stratification strategies to guide treatment intensity

Key Points for Physicians:

• With significant survival data, combination therapy may become the default with an “opt-out” approach
• Liquid biopsy (circulating tumor DNA clearance) can help stratify patients who might benefit from treatment escalation
• All treatments (chemotherapy, amivantamab, EGFR inhibitors) will likely be used at some point in the disease course

Notable Insights:

Treatment sequencing must consider that not all patients receive 2L therapy, making it critical to optimize 1L treatment selection.

Clinical Significance:

A nuanced approach to 1L therapy involves balancing evidence-based recommendations with individualized assessment of risk and patient preferences.